Luminespib

Luminespib
Names
	Preferred IUPAC name 5-[2,4-Dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide
	Other names NVP-AUY-922; AUY922; VER-52296
Identifiers
CAS Number	747412-49-3 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:83656 ;
ChEMBL	ChEMBL252164 ;
ChemSpider	21377936 ;
DrugBank	DB11881;
KEGG	D10646 ;
PubChem CID	135539077;
UNII	C6V1DAR5EB;
CompTox Dashboard (EPA)	DTXSID001336117 ;
	InChI InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32) Key: NDAZATDQFDPQBD-UHFFFAOYSA-N ; InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32);
	SMILES CC(C)c1cc(c(O)cc1O)c2onc(C(=O)NCC)c2c3ccc(cc3)CN4CCOCC4;
Properties
Chemical formula	C26H31N3O5
Molar mass	465.550 g·mol−1
Appearance	Colorless solid
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Luminespib (INN,^[2] previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis^[3] and licensed to Novartis.^[4] From 2011 to 2014 it was in Phase II clinical trials.^[5]^[6] Chemically it is a resorcinylic isoxazole amide^[6]

Luminespib is an inhibitor of heat shock protein 90 (Hsp90),^[1] which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. Luminespib has shown promising activity in preclinical testing against several different tumor types.^[7]^[8]^[9]^[10]

A related compound, NVP-HSP990, was abandoned by Novartis in 2012 after it failed to show efficacy in an early clinical trial.^[6]

References

^ ^a ^b Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jenifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M. (2008). "4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer". Journal of Medicinal Chemistry. 51 (2): 196–218. doi:10.1021/jm701018h. PMID 18020435.
^ "WHO Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 70" (PDF). World Health Organization. pp. 297–8. Retrieved 16 July 2016.
^ "Structure-based design of cancer therapeutics" (PDF). The Institute of Cancer Research. Archived from the original (PDF) on 2011-06-25. Retrieved 2011-10-25.
^ "AUY922". Vernalis. Archived from the original on 2011-09-29.
^ "Small caps: Vernalis drug fillip". Financial Times. July 19, 2011.
^ ^a ^b ^c Sidera, K.; Patsavoudi, E. (Jan 2014). "HSP90 inhibitors: current development and potential in cancer therapy". Recent Patents on Anti-Cancer Drug Discovery. 9 (1): 1–20. doi:10.2174/15748928113089990031. PMID 23312026.
^ Jensen, Michael; Schoepfer, Joseph; Radimerski, Thomas; Massey, Andrew; Guy, Chantale T; Brueggen, Josef; Quadt, Cornelia; Buckler, Alan; Cozens, Robert (2008). "NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models". Breast Cancer Research. 10 (2): R33. doi:10.1186/bcr1996. PMC 2397535. PMID 18430202.
^ Gaspar, N.; Sharp, S. Y.; Eccles, S. A.; Gowan, S.; Popov, S.; Jones, C.; Pearson, A.; Vassal, G.; Workman, P. (2010). "Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma". Molecular Cancer Therapeutics. 9 (5): 1219–1233. doi:10.1158/1535-7163.MCT-09-0683. PMC 2875164. PMID 20457619.
^ Okui, T; Shimo, T; Hassan, NM; Fukazawa, T; Kurio, N; Takaoka, M; Naomoto, Y; Sasaki, A (2011). "Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma". Anticancer Research. 31 (4): 1197–204. PMID 21508365.
^ Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; De Haven Brandon, A.; Gowan, S. (2008). "NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis". Cancer Research. 68 (8): 2850–2860. doi:10.1158/0008-5472.CAN-07-5256. PMID 18413753.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Brough-1] Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jenifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M. (2008). "4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer". Journal of Medicinal Chemistry. 51 (2): 196–218. doi:10.1021/jm701018h. PMID 18020435.

[2] "WHO Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 70" (PDF). World Health Organization. pp. 297–8. Retrieved 16 July 2016.

[3] "Structure-based design of cancer therapeutics" (PDF). The Institute of Cancer Research. Archived from the original (PDF) on 2011-06-25. Retrieved 2011-10-25.

[4] "AUY922". Vernalis. Archived from the original on 2011-09-29.

[5] "Small caps: Vernalis drug fillip". Financial Times. July 19, 2011.

[Sidera2014rev-6] Sidera, K.; Patsavoudi, E. (Jan 2014). "HSP90 inhibitors: current development and potential in cancer therapy". Recent Patents on Anti-Cancer Drug Discovery. 9 (1): 1–20. doi:10.2174/15748928113089990031. PMID 23312026.

[7] Jensen, Michael; Schoepfer, Joseph; Radimerski, Thomas; Massey, Andrew; Guy, Chantale T; Brueggen, Josef; Quadt, Cornelia; Buckler, Alan; Cozens, Robert (2008). "NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models". Breast Cancer Research. 10 (2): R33. doi:10.1186/bcr1996. PMC 2397535. PMID 18430202.

[8] Gaspar, N.; Sharp, S. Y.; Eccles, S. A.; Gowan, S.; Popov, S.; Jones, C.; Pearson, A.; Vassal, G.; Workman, P. (2010). "Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma". Molecular Cancer Therapeutics. 9 (5): 1219–1233. doi:10.1158/1535-7163.MCT-09-0683. PMC 2875164. PMID 20457619.

[9] Okui, T; Shimo, T; Hassan, NM; Fukazawa, T; Kurio, N; Takaoka, M; Naomoto, Y; Sasaki, A (2011). "Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma". Anticancer Research. 31 (4): 1197–204. PMID 21508365.

[10] Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; De Haven Brandon, A.; Gowan, S. (2008). "NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis". Cancer Research. 68 (8): 2850–2860. doi:10.1158/0008-5472.CAN-07-5256. PMID 18413753.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

See also

References